Radiation dose and checkpoint blockade immunotherapy: Unanswered questions

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages e3-e4

  Monjazeb, Arta M ^a   Schoenfeld, Jonathan D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DEATH; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPOFRACTIONATED RADIOTHERAPY; LETTER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; CHEMORADIOTHERAPY; DRUG EFFECTS; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHEMORADIOTHERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 84955285897     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00541-0     Document Type: Letter

References (8)

1. Sharabi AB, Lim M, DeWeese TL, Drake CG Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015, 16:e498-e509.
2. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective t cell immunotherapy. Cancer Cell 2013, 24:589-602.
3. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004, 64:4328-4337.
4. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
5. Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015, 4:e1046028.
6. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 2015, 16:795-803.
7. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15:700-712. for the CA184-043 Investigators.
8. Victor CT-S, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.